Navigation Links
PAREXEL Reports Second Quarter Fiscal Year 2011 Financial Results
Date:1/31/2011

share grew 11.5%.

On a segment basis, consolidated service revenue for the second quarter of Fiscal Year 2011 was $231.4 million in Clinical Research Services (CRS), $32.0 million in PAREXEL Consulting and Medical Communications Services (PCMS), and $41.0 million in Perceptive Informatics, Inc.

The Company’s low current quarter tax rate benefited from a favorable mix of pre-tax profitability, the extension of certain U.S. tax law provisions, and the ongoing benefit of the Company’s approach to transfer pricing.  At the same time, the Company experienced higher than anticipated foreign exchange losses on the Other Expense line, in part due to a short-term disruption to cash flows caused by implementation of the Company’s new billing system.  The Company substantially increased billing during the December quarter, reducing days sales outstanding sequentially to 69 days, while increasing deferred revenue, and decreasing unbilled receivables.

For the six months ended December 31, 2010, consolidated service revenue was $600.2 million versus $544.5 million in the prior year period, an increase of 10.2%.  GAAP operating income for the current six-month period was $58.2 million, or 9.7% of service revenue, compared with GAAP operating income of $37.2 million, or 6.8% of service revenue in the prior year period.  GAAP net income for the six months ended December 31, 2010 was $34.6 million, or $0.58 per diluted share, compared with GAAP net income of $15.9 million, or $0.27 per diluted share, in the prior year period.  Excluding the impact of certain items as detailed in the attached financial charts in both six month periods, operating income was $57.2 million or 9.5% of consolidated service revenue for the six months ended on December 31, 2010, compared with $45.4 million or 8.3% of consolidated service revenue for the six months ended on December 31, 2009.  On an adjusted basis, net income for the six mo
'/>"/>

SOURCE PAREXEL International Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. PAREXEL Announces Date of Second Quarter Fiscal Year 2011 Earnings Release and Conference Call
2. Edwin Rivera-Martinez, Former Chief of the FDA’s International Compliance Branch, Joins PAREXEL Consulting Strategic Compliance Team
3. PAREXEL Announces Date of First Quarter Fiscal Year 2011 Earnings Release and Conference Call
4. PAREXEL Issues Updated Financial And Operational Information
5. PAREXEL Consulting Releases New Study Data on Drug Development Timelines in Safety First Era
6. PAREXEL International to Present at Thomas Weisel Partners Healthcare Conference
7. PAREXEL International to Present at Robert Baird 2009 Healthcare Conference
8. PAREXEL Announces Date of Fourth Quarter and Fiscal Year 2009 Earnings Release and Conference Call
9. PAREXEL International to Present at the Wachovia Equity Conference
10. PAREXEL Experts to Present Leading Insights at Drug Information Association 45th Annual Meeting
11. PAREXEL Consulting Experts To Present Insights Into Achieving Regulatory Approval at the 2009 BIO International Convention
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014 /CNW/ - Sunovion Pharmaceuticals ... APTIOM TM (eslicarbazepine acetate) for use as a ... in patients with epilepsy who are not satisfactorily controlled ... for use in patients under 18 years of age. ... common neurological disorders and according to Epilepsy Canada, it ...
(Date:7/10/2014)... UK (PRWEB) July 10, 2014 ... 21st Century Medicine Forum on ‘Commercialising Longevity Research’ ... and entrepreneurs to the London Bioscience Innovation Center ... Research Foundation and Aging Analytics Ltd. The meeting ... investment in translational research for age-related disease, as ...
(Date:7/10/2014)... Los Angeles, CA (PRWEB) July 10, 2014 ... Analytical and Bioanalytical techniques during 18-20 August, 2014 at ... to critically review the recent developments in Analytical & ... across the globe. , Speaking on this occasion, Dr. ... that Analytica Acta conference is a remarkable one ...
(Date:7/10/2014)... , July 10, 2014  Kainos Capital, a ... brands, today announced that it has acquired the Slim-Fast ... in the business. Terms of the transaction were not ... and meal replacement business that markets ready-to-drink shakes, powders, ... North America and in the ...
Breaking Biology Technology:Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 2DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 3DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 5DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 6A Critical Review of Analytical Techniques for Improved Living Standards 2A Critical Review of Analytical Techniques for Improved Living Standards 3A Critical Review of Analytical Techniques for Improved Living Standards 4Kainos Capital Acquires Slim-Fast From Unilever 2
... Investors to Attend Conference, MONTREAL, Sept. 12 ... announced that Mr. Pierre Laurin, President,and Chief Executive ... Investor Summit on September 16, 2008 at 16:00 ... Hopkins InterContinental Hotel in San Francisco., More ...
... Exosome Diagnostics, Inc. today,announced the appointment of ... this role, Dr. Skog will oversee the research ... diagnostics that can,identify cancer-specific genetic mutations., Dr. ... Exosome Diagnostics,core technology that has been licensed exclusively ...
... Catalyst,Pharmaceutical Partners, Inc. (Nasdaq: CPRX ), ... prescription drugs,for the treatment of drug addiction and ... into definitive agreements with,institutional investors to sell 1,488,332 ... $3.00 per share in a registered direct common ...
Cached Biology Technology:ProMetic to present at Merriman Curhan Ford's Investor Summit 2008 on September 16th 2Catalyst Pharmaceutical Partners, Inc. Announces a $4.5 Million Registered Direct Common Stock Offering 2Catalyst Pharmaceutical Partners, Inc. Announces a $4.5 Million Registered Direct Common Stock Offering 3
(Date:7/11/2014)... Standards and Technology (NIST) need a special tool ... prove that necessity is truly the mother of ... Lorna De Leoz and Stephen Stein, NIST chemists ... is the study of the abundant, often-branched sugar ... and lipids and influence cellular processes, including immunity, ...
(Date:7/11/2014)... international team of researchers, including scientists from the Max ... a reported a major step in understanding photosynthesis, the ... maintains the oxygen in its atmosphere and which is ... earth. , The researchers report the first direct ... namely the step in which a specific protein complex, ...
(Date:7/11/2014)... mesenchymal stem cells can stimulate neurogenesis in the brain ... (AD) and improve tissue and function injury under the ... the therapeutic effect of adipose-derived stem cells (ADSCs) transplantation ... oxidative injury and neurogenesis in the brain of AD ... Life Sciences, Tsinghua University, China transplanted ADSCs into the ...
Breaking Biology News(10 mins):A first direct glimpse of photosynthesis in action 2
... This release is available in <A HREF=",http://chinese.eurekalert.org/zh/pub_releases/2009-05/bc-pmp051909.php,">Chinese . ... in plants is able to take on a similar ... in the open access journal BMC Microbiology . ... in E. coli cells, polar regions keeping ...
... has been thrown on how humans choose their partners, ... European Society of Human Genetics today (Monday May 25). ... Immunogenetics and Histocompatibility Laboratory at the University of Parana, ... with diverse major histocompatibility complexes (MHCs) were more likely ...
... Molecular Medicine (MDC) Berlin-Buch, Germany, have gained crucial insight ... the sensory neurons of mice, the neurobiologists and pain ... were able to directly elucidate, for the first time, ... were able to show that neurons develop their sensitivity ...
Cached Biology News:Plant Min protein sits tight and rescues E. coli 2Opposites attract -- how genetics influences humans to choose their mates 2Investigating the development of mechanosensitivity 2
Rat monoclonal to UGGT ( Abpromise for all tested applications)....
... polyclonal to MSY2/YBOX2 ( Abpromise ... Antigen: Synthetic peptide derived ... C-terminus of Human MSY2/YBOX2. (Note: ... (Peptide available as ...
...
Request Info...
Biology Products: